Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals and Vivo Capital Launch Joint Venture Aimed at Greater China Market

Retrieved on: 
Monday, April 25, 2022
Health, Genetics, Other Health, General Health, Pharmaceutical, Biotechnology, News, CEO, Arrowhead, Biotechnology, RNA interference, Lists of diseases, U.S. Securities and Exchange Commission, COVID-19, Security (finance), Twitter, NASDAQ, Licensed production, Gene silencing, Annual report, Private Securities Litigation Reform Act, RNA, Vivo, Company, Patient, Ecosystem, Arrowhead Pharmaceuticals, Mission statement, Gene, Safety, Therapy, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Pharmaceutical industry

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has formed a joint venture, Visirna Therapeutics, with Vivo Capital to expand the reach of innovative medicines in Greater China.

Key Points: 
  • Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has formed a joint venture, Visirna Therapeutics, with Vivo Capital to expand the reach of innovative medicines in Greater China.
  • Greater China is an important region for global pharmaceutical products broadly, and specifically for medicines that treat cardiovascular and metabolic diseases.
  • We deeply appreciate our partners at Arrowhead entrusting us with the development of these valuable assets for Chinese patients, commented Dr. Hongbo Lu, Managing Partner of Vivo Capital.
  • Founded in 1996, Vivo Capital is a leading global healthcare investment firm with a diverse, multi-fund investment platform in venture capital, growth equity, buyout, and public equities.

Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Second Quarter Results

Retrieved on: 
Wednesday, April 20, 2022
Infectious Diseases, FDA, Genetics, Clinical Trials, Cardiology, Biotechnology, General Health, Pharmaceutical, Health, Oncology, News, Arrowhead, RNA interference, U.S. Securities and Exchange Commission, COVID-19, Security (finance), Twitter, NASDAQ, Gene silencing, Annual report, Private Securities Litigation Reform Act, RNA, Conference, Company, Webcast, Arrowhead Pharmaceuticals, Mission statement, Gene, Safety, Therapy, Merrell Dow Pharmaceuticals Inc. v. Thompson, Pharmaceutical industry

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 10, 2022, at 4:30 p.m.

Key Points: 
  • Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 10, 2022, at 4:30 p.m.
  • ET to discuss its financial results for the fiscal 2022 second quarter ended March 31, 2022.
  • The forward-looking statements in the webcast speak only as of the original date of the webcast.
  • We assume no obligation to update or revise forward-looking statements contained in the webcast to reflect new events or circumstances.

Global RNAi Therapeutics Market Report 2022-2026 Featuring Sanofi., Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Arbutus Biopharma, Benitec Biopharma, and Sirnaomics

Retrieved on: 
Wednesday, April 20, 2022
Molecule, Sirna Therapeutics, Degenerative disease, MicroRNA, COVID-19, Lists of diseases, Research, Benitec Biopharma, RNA, Hospital, CAGR, RNA interference, Infection, Liver, Investment, HTS, Arrowhead Pharmaceuticals, Prevalence, Neurodegeneration, Therapy, Pharmaceutical industry, Medical device

DUBLIN, April 20, 2022 /PRNewswire/ --The "Global RNAi Therapeutics Market (by Molecule Type, Application, End-User & Region): Insights & Forecast with Potential Impact of COVID-19 (2022-2026)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, April 20, 2022 /PRNewswire/ --The "Global RNAi Therapeutics Market (by Molecule Type, Application, End-User & Region): Insights & Forecast with Potential Impact of COVID-19 (2022-2026)" report has been added to ResearchAndMarkets.com's offering.
  • The global RNAi therapeutics market is expected to record a value of US$1.15 billion in 2026, progressing at a CAGR of 10.19%, over the period 2022-2026.
  • However, the market growth would be challenged by complexity associated with the drug delivery of RNAi therapeutics, high development cost of RNA interference-based therapeutics and stringent regulatory requirements.
  • Whereas, the global RNAi therapeutics market is split into research & academic laboratories and hospitals & diagnostic laboratories, in terms of end-user.

Global RNAi Therapeutics Market Analysis/Research Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 14, 2022
Biotechnology, Pharmaceutical, Health, Molecule, Sirna Therapeutics, Degenerative disease, MicroRNA, COVID-19, Lists of diseases, Research, Benitec Biopharma, RNA, Hospital, CAGR, RNA interference, Infection, Liver, Investment, HTS, Arrowhead Pharmaceuticals, Prevalence, Neurodegeneration, Therapy, Pharmaceutical industry, Medical device

The "Global RNAi Therapeutics Market (by Molecule Type, Application, End-User & Region): Insights & Forecast with Potential Impact of COVID-19 (2022-2026)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global RNAi Therapeutics Market (by Molecule Type, Application, End-User & Region): Insights & Forecast with Potential Impact of COVID-19 (2022-2026)" report has been added to ResearchAndMarkets.com's offering.
  • The global RNAi therapeutics market is expected to record a value of US$1.15 billion in 2026, progressing at a CAGR of 10.19%, over the period 2022-2026.
  • However, the market growth would be challenged by complexity associated with the drug delivery of RNAi therapeutics, high development cost of RNA interference-based therapeutics and stringent regulatory requirements.
  • Whereas, the global RNAi therapeutics market is split into research & academic laboratories and hospitals & diagnostic laboratories, in terms of end-user.

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Retrieved on: 
Wednesday, April 6, 2022
Health, Medical Devices, Infectious Diseases, Genetics, General Health, Pharmaceutical, Biotechnology, Company, Arrowhead Pharmaceuticals, Therapy, NASDAQ, RNA, Employment, Arrowhead, RNA interference, Twitter, Financial compensation, Gene, Gene silencing, News, Vaccine

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on April 1, 2022, the Compensation Committee of the Companys Board of Directors approved inducement grants to 23 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules.

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on April 1, 2022, the Compensation Committee of the Companys Board of Directors approved inducement grants to 23 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules.
  • The grants entitle employees, in aggregate, to receive up to 53,000 restricted stock units.
  • The grants are outside the Companys stockholder-approved equity incentive plans and vest annually over four years.
  • Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them.

Arrowhead Pharmaceuticals to Participate in Upcoming April 2022 Conferences

Retrieved on: 
Friday, April 1, 2022
Biotechnology, Pharmaceutical, General Health, Health, Medical Devices, Infectious Diseases, Hospitals, Other Health, Company, Private Securities Litigation Reform Act, Hepatitis B virus, Safety, Arrowhead Pharmaceuticals, Therapy, NASDAQ, Oligonucleotide, Investor, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., RNA interference, AACR, Pharmacokinetics, American Association, Conference, Mission statement, RNA, U.S. Securities and Exchange Commission, Arrowhead, Association, American Association for Cancer Research, Twitter, COVID-19, Gene, Gene silencing, News, Annual report, Security (finance), Vaccine, Liver

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them.

Key Points: 
  • Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them.
  • Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes.
  • Any statements contained in this release except for historical information may be deemed to be forward-looking statements.
  • We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MUC5AC for Treatment of Muco-Obstructive Lung Diseases

Retrieved on: 
Thursday, March 24, 2022
Research, Other Health, General Health, Pharmaceutical, Medical Devices, Infectious Diseases, Genetics, Clinical Trials, Science, Cardiology, Biotechnology, FDA, Health, Company, Private Securities Litigation Reform Act, MUC5AC, Arrowhead Pharmaceuticals, Therapy, NASDAQ, Ethics committee, D, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Committee, Clinical trial, Pharmacokinetics, Mission statement, RNA, U.S. Securities and Exchange Commission, Arrowhead, RNA interference, Mucus, Review, Safety, Twitter, COVID-19, MBA, Gene, Gene silencing, News, Asthma, Annual report, Patient, Security (finance), Pharmaceutical industry

Arrowhead also announced plans to host a pulmonary R&D day on May 26, 2022, to be held in New York and webcast online.

Key Points: 
  • Arrowhead also announced plans to host a pulmonary R&D day on May 26, 2022, to be held in New York and webcast online.
  • Additional details about the event and how to register will be released in the coming weeks.
  • We look forward to sharing additional information about ARO-MUC5AC, ARO-RAGE, and Arrowheads pulmonary platform broadly at our upcoming pulmonary R&D day.
  • Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them.

Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-RAGE for Treatment of Asthma

Retrieved on: 
Tuesday, March 15, 2022
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, RNA interference, Twitter, Trial of the century, MBA, Pharmacokinetics, Private Securities Litigation Reform Act, Annual report, Review, Patient, News, RAGE, Therapy, COVID-19, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Arrowhead, Safety, Arrowhead Pharmaceuticals, Committee, Security (finance), Asthma, NASDAQ, Gene silencing, Ethics committee, Clinical trial, Company, Serum, U.S. Securities and Exchange Commission, Gene, Mission statement, RNA, Pharmaceutical industry

James Hamilton, M.D., MBA, senior vice president of discovery and translational medicine at Arrowhead, said: ARO-RAGE is a new clinical candidate using the pulmonary targeted, inhaled TRiM platform.

Key Points: 
  • James Hamilton, M.D., MBA, senior vice president of discovery and translational medicine at Arrowhead, said: ARO-RAGE is a new clinical candidate using the pulmonary targeted, inhaled TRiM platform.
  • We believe RAGE is a promising target as it represents an upstream mediator of the inflammatory cascade in asthma.
  • Importantly, a soluble form of RAGE known as sRAGE can be assessed as a useful serum biomarker to measure gene target knockdown.
  • Pending clearance, Arrowhead intends to proceed with ARORAGE-1001, a Phase 1/2a study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-RAGE in up to 64 healthy volunteers and in up to 16 patients with asthma.

Crinetics Pharmaceuticals Expands Executive Team with Appointment of James Hassard as Chief Commercial Officer

Retrieved on: 
Tuesday, March 1, 2022
GLOBE, Pharmacology, Congenital hyperinsulinism, Therapy, Arrowhead Pharmaceuticals, Annual report, ACTH, Employment, Congenital adrenal hyperplasia, Securities Exchange Act of 1934, Wilms' tumor, Nova Southeastern University, University, Amgen, Disease, Acromegaly, Cinacalcet, Endocrinology, SST2, Nephrology, CAH, FDA, SAN, Securities Act of 1933, Drug discovery, Marketing, Patient, Carcinoid syndrome, Degenerative disease, Nasdaq, Â, Form 10-K, Business administration, Research, SEC, Pharmaceutical industry, Science

(Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the appointment of James Hassard as chief commercial officer.

Key Points: 
  • (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the appointment of James Hassard as chief commercial officer.
  • Mr. Hassard is a commercial leader with more than three decades of experience leading sales and marketing operations for both global and domestic biotechnology companies.
  • Scott Struthers, Ph.D. , founder and chief executive officer ofCrinetics, stated, In addition to his deep biopharmaceutical experience, Jims background as a pharmacologist gives him valuable scientific insight that informs his commercial strategy.
  • Prior to joining Crinetics, Jim Hassard was chief commercial officer at Arrowhead Pharmaceuticals, Inc., where he began building the companys commercial capabilities and launch strategy for three rare disease programs.

Arrowhead Completes Enrollment in Phase 2b ARCHES-2 Study of Investigational ARO-ANG3 for Patients with Mixed Dyslipidemia

Retrieved on: 
Thursday, February 24, 2022
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Apolipoprotein, Arrowhead, Arrowhead Pharmaceuticals, Therapy, Population, Twitter, Lipoprotein lipase, RNA, Serum, NASDAQ, Security (finance), Gene, Annual report, COVID-19, Company, Private Securities Litigation Reform Act, Concentration ratio, Safety, Mission statement, U.S. Securities and Exchange Commission, ANGPTL3, News, TG, RNA interference, Gene silencing, Patient, Cardiovascular disease, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., LDL, Pharmaceutical industry

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has reached full planned enrollment of more than 180 participants in the Phase 2b ARCHES-2 clinical study of ARO-ANG3, the companys investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with mixed dyslipidemia.

Key Points: 
  • Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has reached full planned enrollment of more than 180 participants in the Phase 2b ARCHES-2 clinical study of ARO-ANG3, the companys investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with mixed dyslipidemia.
  • I want to thank the participating investigators and our entire clinical team for their hard work to enroll this study rapidly and effectively.
  • ARCHES-2, also called AROANG3-2001 ( NCT04832971 ), is a double-blind, placebo-controlled Phase 2b study to evaluate the efficacy and safety of investigational ARO-ANG3 in adults with mixed dyslipidemia.
  • Up to approximately 20 additional participants that were still in screening when the study reached full enrollment may also be enrolled.